These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

383 related articles for article (PubMed ID: 36847998)

  • 41. Genome characterization of a Klebsiella pneumoniae co-producing OXA-181 and KPC-121 resistant to ceftazidime/avibactam, meropenem/vaborbactam, imipenem/relebactam and cefiderocol isolated from a critically ill patient.
    Gaibani P; Amadesi S; Lazzarotto T; Ambretti S
    J Glob Antimicrob Resist; 2022 Sep; 30():262-264. PubMed ID: 35777673
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Efficacy and
    Cruz-López F; Martínez-Meléndez A; Morfin-Otero R; Rodriguez-Noriega E; Maldonado-Garza HJ; Garza-González E
    Front Cell Infect Microbiol; 2022; 12():884365. PubMed ID: 35669117
    [TBL] [Abstract][Full Text] [Related]  

  • 43. In-Vitro Efficacy of Cefiderocol in Carbapenem-Non-Susceptible Gram-Negative Bacilli of Different Genotypes in Sub-Region of North Rhine Westphalia, Germany.
    Ghebremedhin B; Ahmad-Nejad P
    Pathogens; 2021 Sep; 10(10):. PubMed ID: 34684208
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Epidemiology of Carbapenem Resistance Determinants Identified in Meropenem-Nonsusceptible
    Kazmierczak KM; Karlowsky JA; de Jonge BLM; Stone GG; Sahm DF
    Antimicrob Agents Chemother; 2021 Jun; 65(7):e0200020. PubMed ID: 33972241
    [TBL] [Abstract][Full Text] [Related]  

  • 45. An Update on Eight "New" Antibiotics against Multidrug-Resistant Gram-Negative Bacteria.
    Yusuf E; Bax HI; Verkaik NJ; van Westreenen M
    J Clin Med; 2021 Mar; 10(5):. PubMed ID: 33806604
    [TBL] [Abstract][Full Text] [Related]  

  • 46. An Appraisal of the Pharmacokinetic and Pharmacodynamic Properties of Meropenem-Vaborbactam.
    Wenzler E; Scoble PJ
    Infect Dis Ther; 2020 Dec; 9(4):769-784. PubMed ID: 33025557
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Activity of Cefiderocol Against
    Iregui A; Khan Z; Landman D; Quale J
    Microb Drug Resist; 2020 Jul; 26(7):722-726. PubMed ID: 32031915
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Carbapenem-Resistant
    Karampatakis T; Tsergouli K; Behzadi P
    Antibiotics (Basel); 2023 Jan; 12(2):. PubMed ID: 36830145
    [No Abstract]   [Full Text] [Related]  

  • 49. Synergistic Effect of Clinically Available Beta-Lactamase Inhibitors Combined with Cefiderocol against Carbapenemase-Producing Gram-Negative Organisms.
    Bianco G; Gaibani P; Comini S; Boattini M; Banche G; Costa C; Cavallo R; Nordmann P
    Antibiotics (Basel); 2022 Nov; 11(12):. PubMed ID: 36551337
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Sulfamoyl Heteroarylcarboxylic Acids as Promising Metallo-β-Lactamase Inhibitors for Controlling Bacterial Carbapenem Resistance.
    Wachino JI; Jin W; Kimura K; Kurosaki H; Sato A; Arakawa Y
    mBio; 2020 Mar; 11(2):. PubMed ID: 32184250
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Cefiderocol for the Treatment of Multidrug-Resistant Gram-Negative Bacteria: A Systematic Review of Currently Available Evidence.
    Wang C; Yang D; Wang Y; Ni W
    Front Pharmacol; 2022; 13():896971. PubMed ID: 35496290
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Changing Epidemiology of Carbapenemases Among Carbapenem-Resistant Enterobacterales From United States Hospitals and the Activity of Aztreonam-Avibactam Against Contemporary Enterobacterales (2019-2021).
    Sader HS; Mendes RE; Carvalhaes CG; Kimbrough JH; Castanheira M
    Open Forum Infect Dis; 2023 Feb; 10(2):ofad046. PubMed ID: 36846612
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Investigator-Driven Randomised Controlled Trial of Cefiderocol versus Standard Therapy for Healthcare-Associated and Hospital-Acquired Gram-negative Bloodstream Infection: Study protocol (the GAME CHANGER trial): study protocol for an open-label, randomised controlled trial.
    Wright H; Harris PNA; Chatfield MD; Lye D; Henderson A; Harris-Brown T; Donaldson A; Paterson DL
    Trials; 2021 Dec; 22(1):889. PubMed ID: 34876196
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Activity of meropenem/vaborbactam and comparators against non-carbapenemase-producing carbapenem-resistant Enterobacterales isolates from Europe.
    Shortridge D; Deshpande LM; Streit JM; Castanheira M
    JAC Antimicrob Resist; 2022 Oct; 4(5):dlac097. PubMed ID: 36196439
    [TBL] [Abstract][Full Text] [Related]  

  • 55. The Battle Is on: New Beta-Lactams for the Treatment of Multidrug-Resistant Gram-Negative Organisms.
    Noval M; Banoub M; Claeys KC; Heil E
    Curr Infect Dis Rep; 2020 Jan; 22(1):1. PubMed ID: 31933158
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Evaluating the Efficacies of Carbapenem/β-Lactamase Inhibitors Against Carbapenem-Resistant Gram-Negative Bacteria
    El Hafi B; Rasheed SS; Abou Fayad AG; Araj GF; Matar GM
    Front Microbiol; 2019; 10():933. PubMed ID: 31114565
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Novel Specific Metallo-β-Lactamase Inhibitor ANT2681 Restores Meropenem Activity to Clinically Effective Levels against NDM-Positive
    Zalacain M; Lozano C; Llanos A; Sprynski N; Valmont T; De Piano C; Davies D; Leiris S; Sable C; Ledoux A; Morrissey I; Lemonnier M; Everett M
    Antimicrob Agents Chemother; 2021 May; 65(6):. PubMed ID: 33820763
    [TBL] [Abstract][Full Text] [Related]  

  • 58.
    Hernández-García M; García-Castillo M; Ruiz-Garbajosa P; Bou G; Siller-Ruiz M; Pitart C; Gracia-Ahufinger I; Mulet X; Pascual Á; Tormo N; Cantón R
    Antimicrob Agents Chemother; 2022 Mar; 66(3):e0216121. PubMed ID: 35007130
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Treatment of urinary tract infections in the era of antimicrobial resistance and new antimicrobial agents.
    Bader MS; Loeb M; Leto D; Brooks AA
    Postgrad Med; 2020 Apr; 132(3):234-250. PubMed ID: 31608743
    [TBL] [Abstract][Full Text] [Related]  

  • 60. In vitro activity of the novel siderophore cephalosporin, cefiderocol, in Gram-negative pathogens in Europe by site of infection.
    Candel FJ; Santerre Henriksen A; Longshaw C; Yamano Y; Oliver A
    Clin Microbiol Infect; 2022 Mar; 28(3):447.e1-447.e6. PubMed ID: 34298176
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 20.